SAB BIOTHERAPEUTICS, INC. (SABS) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -71.82M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 49.27M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-71.82M | (m) | (m) | $49.27M | (m) | (m) |
| 2026-03-31 | $-58.18M | (m) | (m) | $40.09M | (m) | (m) |
| 2025-12-31 | $-48.95M | $0.00 | (m) | $34.35M | (m) | (m) |
| 2025-09-30 | $-43.19M | (m) | (m) | $31.28M | (m) | (m) |
| 2025-06-30 | $-41.82M | (m) | (m) | $30.14M | (m) | (m) |
| 2025-03-31 | $-42.29M | (m) | (m) | $29.76M | (m) | (m) |
| 2024-12-31 | $-42.91M | $1.32M | (m) | $30.25M | (m) | -3244.87% |
| 2024-09-30 | $-51.78M | $1.51M | (m) | $26.90M | (m) | -3422.67% |
| 2024-06-30 | $-45.79M | $2.78M | (m) | $23.09M | (m) | -1647.04% |
| 2024-03-31 | $-42.06M | $2.60M | (m) | $20.13M | (m) | -1616.31% |
| 2023-12-31 | $-38.08M | $2.24M | (m) | $16.52M | (m) | -1700.56% |
| 2023-09-30 | $-27.06M | $4.09M | (m) | $19.36M | (m) | -660.87% |
| 2023-06-30 | $-29.55M | $6.42M | (m) | $22.69M | (m) | -460.42% |
| 2023-03-31 | $-29.61M | $12.68M | (m) | $27.65M | (m) | -233.49% |
| 2022-12-31 | $-28.92M | $23.90M | (m) | $36.44M | (m) | -120.97% |
| 2022-09-30 | $-28.40M | $32.80M | (m) | $39.95M | (m) | -86.59% |
| 2022-06-30 | $-24.58M | $43.89M | (m) | $47.67M | (m) | -56.01% |
| 2022-03-31 | $-20.91M | $55.75M | (m) | $57.73M | (m) | -37.51% |
| 2021-12-31 | $-13.39M | $60.88M | (m) | $57.18M | (m) | -22.00% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $20.56M | $55.24M | (m) | $27.91M | (m) | 37.22% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |